Growth Metrics

Nexalin Technology (NXL) EBIT (2021 - 2025)

Nexalin Technology (NXL) has 5 years of EBIT data on record, last reported at -$2.3 million in Q3 2025.

  • For Q3 2025, EBIT rose 6.49% year-over-year to -$2.3 million; the TTM value through Sep 2025 reached -$8.9 million, down 36.12%, while the annual FY2024 figure was -$7.8 million, 36.13% down from the prior year.
  • EBIT reached -$2.3 million in Q3 2025 per NXL's latest filing, down from -$1.6 million in the prior quarter.
  • Across five years, EBIT topped out at -$293194.0 in Q3 2022 and bottomed at -$2.9 million in Q4 2024.
  • Average EBIT over 5 years is -$1.4 million, with a median of -$1.3 million recorded in 2024.
  • Peak YoY movement for EBIT: skyrocketed 83.67% in 2022, then plummeted 723.87% in 2023.
  • A 5-year view of EBIT shows it stood at -$577489.0 in 2021, then decreased by 24.61% to -$719617.0 in 2022, then tumbled by 125.74% to -$1.6 million in 2023, then plummeted by 77.0% to -$2.9 million in 2024, then increased by 18.42% to -$2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$2.3 million in Q3 2025, -$1.6 million in Q2 2025, and -$2.0 million in Q1 2025.